Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

Provence and Neuroptis Biotech Partner to Develop a New Compound for Treating Dry Eye Syndrome

Published: Wednesday, May 23, 2012
Last Updated: Wednesday, May 23, 2012
Bookmark and Share
Provence Technologies to optimize and transfer the production process for ML7, Neuroptis Biotech’s dry eye drug candidate.

Provence Technologies and Neuroptis Biotech have announced the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012.

ML7 is a drug candidate for the treatment of dry eye syndromes. It is the first of a new therapeutic class and has the potential to provide a targeted and effective therapeutic remedy for the millions of people suffering from dry eye syndrome, Gougerot-Sjogren syndrome and inflammations, especially ones caused by allergies.

Provence Technologies and Neuroptis Biotech have already collaborated successfully in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches and devising associated analytical methods.

The two companies have embarked on the process optimization phase to facilitate the transfer of the compound and the start of production on an industrial scale, scheduled for September this year.

“Our know-how in the area of organic synthesis, process development and the management of fine chemistry projects enabled us to handle the chemical development of this drug candidate and produce the first batches of ML7, thereby enabling Neuroptis to begin initial formulation tests,” said Provence Technologies’ chief operating officer, Dr. Babak Sayah.

Dr. Sayah continued, “Our involvement and our tough requirements for undertaking our clients’ projects are strictly the same as those we impose on ourselves for taking our own research and development programs to the commercialization stage.”

“The ML7 development program is a priority for Neuroptis,” said Neuroptis Biotech’s chairman, Dr. Eric Belot. “Our collaboration with Provence Technologies has enabled us to have the first batches of ML7 not only on time but also to a level of purity that means we can proceed to the formulation and toxicity study stages with greater confidence. We have found in Provence Technologies a highly professional partner that has succeeded in managing the project efficiently while keeping us regularly informed with a high degree of transparency during the whole development process.”

Provence Technologies will be participating in Chemoutsourcing at Long Branch, NJ, from 10 to 13 September 2012.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office
The group will also use the investment to set up an incubator for health care industry start-ups.
Thursday, January 30, 2014
Scientific News
Solvent-free, Catalyst-free Peracetylation of Natural Products
In this study, a tunable microwave-assisted method for the solvent-free and catalyst-free peracetylation of natural products was developed.
Sonochemical Reactors
A critical analysis of the underlying mechanisms for intensification, available reactor configurations and overview of the different applications exploited successfully are presented.
Economical and Scalable Synthesis of 6-amino-2-cyanobenzothiazole
An economical and scalable synthesis of ACBT is presented, along with advantages for scale-up over previously reported routes.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos